Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cypher Genomics, Illumina Enter Biomarker Agreement

Published: Saturday, July 26, 2014
Last Updated: Saturday, July 26, 2014
Bookmark and Share
Co-promotion agreement to facilitate genomic biomarker discovery.

Cypher Genomics, Inc. has announced a co-promotion agreement with Illumina to facilitate the development of genomic-based biomarkers from whole genome sequence data for precision medicine and clinical trials.

Cypher Genomics and Illumina will jointly offer pharmaceutical companies, through Illumina's sales force, a solution including Illumina's market leading sequencing technology, the NextBio platform for data analytics and storage, and Cypher Genomics' biomarker discovery service, called Coral™.

Cypher Genomics technology reduces the signal-to-noise in genomic information to uncover important biomarkers in sample sizes typical of early stage drug development studies.

"Cypher Genomics' biomarker discovery service is a perfect complement to Illumina's whole genome sequencing and our NextBio analytics platform," said Nick Naclerio, SVP Corporate Development and General Manager Enterprise Informatics of Illumina. "We look forward to working with Cypher Genomics to provide our mutual customers with the sequencing, data interpretation, and data mining they require for biomarker discovery with whole genome data."

"We founded Cypher Genomics to transform the practice of medicine through fast and accurate genome interpretation. Cypher Genomics' biomarker discovery service, Coral™, includes technology that has a proven track record of success with pharmaceutical companies to discover the genetic basis of response to drug therapy," states Ashley Van Zeeland, Ph.D., co-founder and chief executive officer of Cypher Genomics.

The benefits of biomarker discovery to deliver precision medicine is clear - better tools that can match therapies to patients not only improves clinical outcomes but also reduce clinical trial sizes, which can accelerate time to market for life-saving therapies.

Many desire to look beyond biomarker panels to the whole genome, but biomarker discovery based on whole genome data generally has not been feasible due to the lack of statistical power within the small sample sizes of early clinical studies.

Cypher's genomic analysis platform provides highly accurate genome annotations combined with advanced statistical techniques to enable biomarker discovery studies with sample sizes in the hundreds, reflecting the reality of many Phase 2 clinical trials.

Adam Simpson, president and chief operating officer of Cypher Genomics, added, "Working with Illumina to offer best-in-class sequencing and analysis to pharmaceutical companies enables acceleration of their personalized drug development efforts and will ultimately help deliver on the promise of precision medicine."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
A Better Model for Parkinson's
Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
Microalgae Make a Splash in the UK Cosmeceutical Market
Scottish innovators have discovered an anti-viral and anti-inflammatory carbohydrate in microscopic algae (microalgae) which has huge potential to change the cosmetics market.
Mechanism of Tumor Suppressing Gene Uncovered
The most commonly mutated gene in cancer,p53, works to prevent tumor formation by keeping mobile elements in check that otherwise lead to genomic instability, UT Southwestern Medical Center researchers have found.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
Useful Colon Cancer Biomarker Discovered
Biomarker is detectable with simple, inexpensive test.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Seeing Hope
Gene therapy/drug combo restores some vision in mice with optic nerve injury.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!